Ratos acquires remaining shares in TFS


Ratos has acquired the remaining shares (40%) in the subsidiary Trial Form Support International AB (TFS) from partner and founder Daniel Spasic for an equity value of approximately EUR 11m. After the acquisition, Ratos’s ownership share totals 100%.

Ratos acquired 60% of TFS, an international service provider and a so-called contract research organization (CRO) that conducts clinical trials for pharmaceutical, biotechnology and medical device companies, from founder and owner Daniel Spasic in 2015. With the acquisition of the remaining 40%, Ratos now owns 100% of the company. The acquisition price for the remaining shares amounts to approximately EUR 11m.

“I am delighted that we have reached an agreement with Daniel to acquire the remaining shares of TFS. We strongly believe in this company, which operates in an attractive industry,” says Johan Rydmark, Director at Ratos and responsible for TFS.

TFS has approximately 650 employees and sales for the rolling 12-month period at 30 September 2018 totalled EUR 85.1m. 

For further information, please contact:
Johan Rydmark, Director, Ratos, +46 76 109 94 41 
Helene Gustafsson, Head of IR and Press, Ratos, +46 8 700 17 98 

About Ratos: 
Ratos owns and develops unlisted medium-sized companies in the Nordic countries. Our goal as an active owner is to contribute to long-term and sustainable operational development in the companies we invest in and to make value-generating transactions. Ratos’s portfolio consists of 12 medium-sized Nordic companies and the largest segments in terms of sales are Construction, Industrials and Consumer goods/Commerce. Ratos is listed on Nasdaq Stockholm and has approximately 12,300 employees.